Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Industry News
11/14/2025
Adagene and Third Arc Bio Sign Licensing Deal for Two Masked CD3 T-Cel...
11/14/2025
Adicon to Acquire Crown Bioscience in US$204M Deal
11/13/2025
WuXi AppTec Establishes European Headquarters in Munich
11/13/2025
Alcon Expands China Strategy with Focus on Accessibility and Innovatio...
11/13/2025
Global Pharma and Biotech Leaders Announce New China Investments at CI...
11/13/2025
Biokin Postpones Planned Hong Kong IPO Amid Market Conditions
11/13/2025
Groovy Secures Series A Financing to Advance AI-Driven Drug Discovery ...
11/13/2025
Kind Pharma Secures Over CNY 400M in Series C Financing to Advance L...
11/13/2025
InSilico Files for Hong Kong IPO to Accelerate AI-Driven Drug Discover...
11/13/2025
Kexing Biopharm Files for Hong Kong IPO to Advance Biologic and Target...
11/13/2025
Laekna Grants Qilu Pharma Exclusive Greater China Rights to LAE002 (Af...
11/12/2025
Indian Pharma Firms Secure Key Wins in China's Latest VBP Round
11/12/2025
BeOne Launches Global Phase 1 Trial of FIC CDK2 Degrader BG-75098
11/12/2025
Rona Thera Unveils Promising Phase 1 Data for Long-Acting APOC3 siRNA ...
11/12/2025
Lyell Acquires Global Rights to ICT's Next-Generation CAR-T Therapy LY...
11/12/2025
Brise Secures Over CNY 200M Series A to Advance Pain Management Pipeli...
11/12/2025
Aureka Closes Multi-Million-Dollar Series A to Advance Pipeline and AI...
11/12/2025
DeliNova Raises CNY 60M in Seed and Angel Financing to Advance In Vivo...
11/12/2025
Brightintel Secures Multi-Million CNY Series Pre-A Funding to Advance ...
11/11/2025
Chinese Innovative Drug Companies Report Strong Q3 Results
11/11/2025
Simcere to Manufacture Idorsia's Insomnia Drug in China
11/11/2025
Nona and Umoja Expand Partnership to Advance In‑Vivo CAR‑T Cell Ther...
11/11/2025
SanegeneBio and Eli Lilly Form RNAi Collaboration in Metabolic Disease...
11/11/2025
MeiraGTx and Eli Lilly Form Strategic Partnership to Advance Gene Ther...
11/11/2025
AZ's Evinova and Harbour BioMed Form AI Partnership to Advance Biologi...
11/7/2025
UniXell Secures CNY 100M in Series A+ Financing to Advance Stem Cell ...
11/7/2025
Vigonvita Life Sciences Debuts on HKSE
11/6/2025
Innorna Reportedly Targets $200M Hong Kong IPO to Accelerate Drug Deve...
11/6/2025
AstraZeneca Adds CNY 990M Investment to Qingdao Inhalants Plant
11/6/2025
Lilly Expands AI Collaboration with XtalPi, Ends CNS Research Pact wit...
Page:
1
/
25
Total number of articles:
745
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit